Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5821469 | 0.92 | GPR119 (0.81) | GPR119CYP2C9KCNH2 | |
| SCHEMBL1071583 | 0.92 | GPR119 (0.69) | GPR119CYP2C9KCNH2 | |
| SCHEMBL2542841 | 0.90 | GPR119 (0.80) | GPR119CYP2C9KCNH2 | |
| SCHEMBL3257093 | 0.90 | GPR119 (0.80) | GPR119CYP2C9KCNH2 | |
| SCHEMBL3252605 | 0.89 | GPR119 (0.80) | GPR119CYP2C9KCNH2 | |
| Adp-597 SCHEMBL386884 | 0.89 | GPR119 (1.00) | GPR119CYP2C9KCNH2 | |
| Adp-597 SCHEMBL29645341 | 0.89 | GPR119 (1.00) | GPR119CYP2C9KCNH2 | |
| SCHEMBL392122 | 0.87 | GPR119 (0.84) | GPR119CYP2C9KCNH2 | |
| SCHEMBL3254404 | 0.87 | GPR119 (0.86) | GPR119CYP2C9KCNH2 | |
| SCHEMBL390234 | 0.87 | GPR119 (0.86) | GPR119CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3485878-A1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | Arena Pharmaceuticals, Inc. (US) | 2019-05-22 | — | — | EP | disclosed |
| EP-2547339-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011113947-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | WO | disclosed |
| WO-2010059384-A1 | PROCESS FOR THE PREPARATION OF TRI-SUBSTITUTED PYRIDINE AND TRI-SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL AS GDIR AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-27 | — | — | WO | disclosed |